The Quantellect read.As of Nov 19, 2026, 13 active firms cover Immunome Inc: 12 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $24.00 to $40.00, a moderate spread. The average target of $34.25 sits 104% above the current $16.78. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 11 to 12 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.72 next quarter toward $-2.55 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 active firms
Buy
Strong Buy00%
Buy1292%
Neutral18%
Sell00%
Strong Sell00%
Based on 13 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$34.25
+104.1% upside
Average target across 12 active firms as of Nov 19, 2026 vs $16.78 current
Highest Target$40.00
Average Target$34.25
Lowest Target$24.00
Detailed analyst forecasts for IMNM
Showing 1–14 of 14 named analysts shown · 13 active firms in the rating projection
As of Nov 19, 2026, 12 of 13 active firms rate IMNM a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IMNM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.72
Range $-0.90 – $-0.54 · 7 analysts
Next period, 7 analysts expect Immunome Inc to earn $-0.72 a share (range $-0.90 – $-0.54), versus — a year earlier. Full-year consensus is $-2.50, growing to $-2.55 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $50.4M next year.
Top analysts covering Immunome Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMNM.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$35.00+108.6% to target
Overall win rate
53%
+ Follow
#2
David Nierengarten
Wedbush · Rank #24
Buy
$35.00+108.6% to target
Overall win rate
48%
+ Follow
#3
SL
Sudan Loganathan
Stephens & Co. · Rank #80
Buy
$30.00+78.8% to target
Overall win rate
47%
+ Follow
#4
Brian Cheng
JP Morgan · Rank #87
Buy
No targeton IMNM
Overall win rate
51%
+ Follow
#5
Andrew Berens
Leerink Partners · Rank #162
Buy
$33.00+96.7% to target
Overall win rate
53%
+ Follow
IMNM stock forecast FAQ
What is IMNM's average 12-month price target?+
The 12 active firms with a live target average $34.25 for Immunome Inc over the next 12 months, ranging from a $40.00 high to a $24.00 low, as of Nov 19, 2026.
Is IMNM stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 13 active firms as of Nov 19, 2026, 12 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IMNM?+
The Street-high target is $40.00 (HC Wainwright & Co.), and the Street-low is $24.00 (Stifel). The average of all 12 active-firm targets is $34.25.
How many active Wall Street firms cover IMNM?+
13 active firms have a recognized rating on Immunome Inc as of Nov 19, 2026, and 12 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IMNM?+
Among analysts who currently cover IMNM, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $35.00 target.
What is Immunome Inc's projected EPS for next quarter?+
The consensus estimate is $-0.72 per share (range $-0.90 – $-0.54) across 7 analysts. Full-year EPS is projected at $-2.50, rising to $-2.55 the following year.
How much revenue is Immunome Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $50.4M next year.
Have analysts been upgrading or downgrading IMNM lately?+
As of Nov 19, 2026, 12 of 13 active firms rate IMNM a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMNM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.